Lose 15% of your body weight with GLP-1s * Lose 15% of your body weight with GLP-1s * *In a 68-week placebo-controlled study of 1,961 obese and overweight non-diabetic adults with weight-related conditions, the treatment group receiving semaglutide experienced a mean body weight loss of 15%, compared to 2% of the placebo group
B.et al (2020)
This measurement determines how long a medication stays active in the body and influences dosing schedules
We saw about a 30% increase in GLP-1 cost. HR Director, large manufacturer Many focus group participants reported that their firms will no longer cover GLP-1 agonists for weight loss due to the increases in use and costs
Temperature and molecular stability are closely linked for these treatments
The most common adverse effects of tirzepatide are gastrointestinal, including nausea (occurring in 20-30% of patients), diarrhea, vomiting, constipation, and abdominal discomfort